{"prompt": "['Emicizumab Prophylaxis', 'No Prophylaxis', 'Endpoint', '(N = 35)', '(N = 18)', '% reduction (95% CI)', '95% (77.3%, 99.1%)', 'p-value', '0.0002', '% patients with 0 bleeds (95% CI)', '94.3 (80.8, 99.3)', '50.0 (26.0, 74.0)', 'ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th', 'percentile', 'a.', 'Based on negative binomial regression.', 'In the intra-patient analysis, emicizumab prophylaxis resulted in a statistically significant', '(p = 0.0003) reduction (79%) in bleed rate for treated bleeds compared with previous bypassing agent', 'prophylaxis collected in the NIS prior to enrollment (Table 2).', 'Table 3', 'Intra-Patient Comparison of Annualized Bleed Rate with Emicizumab Prophylaxis', 'versus Previous Bypassing Agent Prophylaxis', 'Emicizumab Prophylaxis', 'Previous Bypassing Agent', 'Endpoint', '(N = 24)', 'Prophylaxis (N = 24)', 'Treated Bleeds', 'ABR (95% CI) [a]', '3.3 (1.3, 8.1)', '15.7 (11.1, 22.3)', '% reduction (95% CI)', '79% (51.4%, 91.1%)', 'p-value', '0.0003', '% patients with 0 bleeds (95% CI)', '70.8 (48.9, 87.4)', '12.5 (2.7, 32.4)', 'Median ABR (IQR)', '0 (0, 2.2)', '12 (5.7, 24.2)', 'ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th', 'percentile', 'a.', 'Based on negative binomial regression.', 'The study evaluated patient-reported hemophilia-related symptoms (painful swellings and presence of', 'joint pain) and physical functioning (pain with movement and difficulty walking far) using the', 'Physical Health Score of the Haemophilia Adult Quality of Life Questionnaire (Haem-A-QoL) for', 'patients aged 18 years. The weekly emicizumab prophylaxis arm (Arm A) showed an improvement', 'compared with the no prophylaxis arm (Arm B) in the Haem-A-QoL Physical Health Subscale score', 'at the Week 25 assessment (Table 3). The improvement in the Physical Health Score was further', 'supported by the Total Score as measured by the Haem-A-QoL at Week 25.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '95 / Protocol MO39129, Version 3']['Table 4', 'Change in Haem-A-QoL Physical Health Score in Patients 1> 18 Years of Age) with', 'No Prophylaxis versus Emicizumab Prophylaxis at Week 25', 'Emicizumab Prophylaxis', 'No Prophylaxis', 'Haem-A-QoL Scores at week 25', '(N = 25[a])', '(N =14[a])', 'Physical Health Score (Score range 0 to 100) [b]', 'Adjusted mean [c]', '32.6', '54.2', 'Difference in adjusted means (95% CI)', '21.6 (7.9, 35.2)', 'p-value', '0.0029', 'a.', 'Number of patients 18 years who completed the Haem-A-QoL questionnaire.', 'b. Lower scores are reflective of better functioning.', 'c.', 'Adjusted for baseline, and baseline by treatment group interaction.', 'The HAVEN 2 study (BH29992; NCT02795767) was a single-arm, multicenter, open-label, clinical', 'study in pediatric males (age < 12 years, or 12-17 years who weigh < 40 kg) with hemophilia A with', 'FVIII inhibitors. Patients received emicizumab prophylaxis at 3 mg/kg once weekly for the first 4', 'weeks followed by 1.5 mg/kg once weekly thereafter.', 'The study evaluated the efficacy of weekly emicizumab prophylaxis, including the efficacy of weekly', 'emicizumab prophylaxis compared with previous episodic (on-demand) and prophylactic bypassing', 'agent treatment in patients who had participated in a NIS prior to enrollment (intra-patient', 'analysis).', 'At the time of the interim analysis, efficacy was evaluated in 23 pediatric patients who were < 12', 'years old and had been receiving weekly emicizumab prophylaxis for at least 12 weeks, including 19', 'patients age 6 to < 12 years and 4 patients age 2 to < 6 years.', 'ABR and percent of patients with zero bleeds were calculated for 23 patients (Table 4). The median', 'observation time for these patients was 38.1 weeks (12.7-41.6 weeks).', 'Table 5', 'Annualized Bleed Rate with Emicizumab Prophylaxis in Pediatric Patients < 12', 'Years of Age (Interim Analysis)', '% Zero Bleeds', 'ABR [a] (95% CI)', 'Median ABR (IQR)', 'Endpoint', '(95% CI)', 'N = 23', 'N = 23', 'N = 23', 'Treated Bleeds', '0.2 (0.1, 0.6)', '0 (0,0)', '87 (66.4, 97.2)', 'All Bleeds', '2.9 (1.8, 4.9)', '1.5 (0, 4.5)', '34.8 (16.4, 57.3)', 'Treated Spontaneous Bleeds', '0.1 (0, 0.5)', '0 (0, 0)', '95.7 (78.1, 99.9)', 'Treated Joint Bleeds', '0.1 (0, 0.5)', '0 (0,0)', '95.7 (78.1, 99.9)', 'Treated Target Joint Bleeds', 'Not Estimable [b]', '0 (0, 0)', '100 (85.2, 100)', 'ABR = annualized bleed rate; CI = confidence interval; IQR = interquartile range, 25th percentile to 75th', 'percentile', 'a.', 'Based on negative binomial regression', 'b. No treated target joint bleeds reported', 'In the intra-patient analysis, 13 pediatric patients who had participated in the NIS had an ABR of', '17.2 (95% CI [12.4, 23.8]) on previous bypassing agent treatment (prophylactic treatment in 12', 'Emicizumab - F. Hoffmann-La Roche Ltd', '96 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}